Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04524689
Title SAR408701 in Combination With Pembrolizumab and Pembrolizumab Alone in Patients With Non-squamous Non-small Cell Lung Cancer (NSQ NSCLC) (CARMEN-LC05)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Sanofi

lung non-squamous non-small cell carcinoma


Carboplatin + Pembrolizumab + SAR408701

Pembrolizumab + SAR408701

Cisplatin + Pembrolizumab + SAR408701


Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST